PRODUCT DATA SHEET

SARS-CoV-2 IgG ELISA Kit

ENZ-KIT170

Highly sensitive SARS-CoV-2 IgG ELISA kit enabling detection of human SARS-CoV-2 IgG in serum.

Product Number/Sizes

ENZ-KIT170-0001	96 wells

- High-sensitivity ELISA enables detection of low amounts of SARS-CoV-2 IgG
- Rapid qualtitive results in under 2 hours
- High-throughput immunoassay measures up to 86 samples per kit

The SARS-CoV-2 IgG ELISA kit is a colorimetric immunoassay kit with results in under 2 hours. Absorbance is read at 450 nm. Measure up to 86 samples with 1 kit.

Product Specifications

ALTERNATIVE NAME:	Coronavirus (COVID-19) IgG
ASSAY TIME:	<2 hours
APPLICATIONS:	ELISA, Colorimetric detection
APPLICATION NOTES:	For the qualitative determination of human SARS-CoV-2 IgG in serum.
SPECIES REACTIVITY:	Human
SHIPPING:	Blue Ice Not Frozen
LONG TERM STORAGE:	+4°C
CONTENTS:	SARS-CoV-2 Antigen Coated Microplate High Positive Control Low Positive Control Negative Control Sample Diluent Wash Buffer Concentrate Stop Solution TMB Substrate HRP Conjugate Plate Sealer
TECHNICAL INFO/PRODUCT NOTES:	SARS-CoV-2 IgG ELISA Kit - Fact Sheet for Healthcare Providers SARS-CoV-2 IgG ELISA Kit - Fact Sheet for Recipients
REGULATORY STATUS:	IVD - For In vitro Diagnostic Use Only, Rx Only - For Prescription Use Only
DISCLAIMER:	The SARS-CoV-2 IgG ELISA Kit is an Enzyme-Linked Immunosorbent Assay (ELISA) intended for qualitative detection of IgG antibodies to SARS-CoV-2 in human serum. The SARS-CoV-2 IgG ELISA Kit is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C 263a, to perform moderate or high complexity tests. Results are for the detection of SARS CoV-2 antibodies. IgG antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. Individuals may have detectable virus present for several weeks following seroconversion. Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities. This test has been validated but FDA's independent review of this validation is pending.

GLOBAL HEADQUARTERS

Enzo Life Sciences, Inc.
10 Executive Blvd
Farmingdale, NY 11735
USA
T 1-800-942-0430
T 1-631-694-7070
F 1-610-941-9252
E info-usa@enzolifesciences.com
www.enzolifesciences.com

EUROPE/ASIA

Enzo Life Sciences (ELS) AG
Industriestrasse 17, Postfach
CH-4415 Lausen
Switzerland
T +41/061 926 89 89
F +41/061 926 89 79
E info-ch@enzolifesciences.com
www.enzolifesciences.com

Negative results do not preclude acute SARS-CoV-2 infection. If acute infection is suspected, direct testing for SARS-CoV-2 is necessary.

Results from antibody testing should not be used to diagnose or exclude acute SARS-CoV-2 infection.

Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.

This test should not be used for screening of donated blood.



Schematic diagram of the assay protocol for the SARS-CoV-2 IgG ELISA Kit.

Revised 01-Jul-20

GLOBAL HEADQUARTERS

Enzo Life Sciences, Inc.
10 Executive Blvd
Farmingdale, NY 11735
USA
T 1-800-942-0430
T 1-631-694-7070
F 1-610-941-9252
E info-usa@enzolifesciences.com
www.enzolifesciences.com

EUROPE/ASIA

Enzo Life Sciences (ELS) AG
Industriestrasse 17, Postfach
CH-4415 Lausen
Switzerland
T +41/061 926 89 89
F +41/061 926 89 79
E info-ch@enzolifesciences.com
www.enzolifesciences.com